Litcius/Paper detail

Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1–2 trial

Mark T. Gladwin, Victor R. Gordeuk, Payal Desai, Caterina P. Minniti, Enrico M. Novelli, Claudia R. Morris, Kenneth I. Ataga, Laura Castro, Susanna A. Curtis, Fuad El Rassi, H. James Ford, Thomas J. Harrington, Elizabeth S. Klings, Sophie Lanzkron, Darla Liles, Jane A. Little, Alecia Nero, Wally R. Smith, James G. Taylor, Ayanna Baptiste, Ward Hagar, Julie Kanter, Amy Kinzie, Temeia Martin, Amina Rafique, Marilyn J. Telen, Christina M. Lalama, Gregory J. Kato, Kaleab Z. Abebe

2024The Lancet Haematology11 citationsDOIOpen Access PDF

Topics & Concepts

MedicineRiociguatPlaceboProteinuriaInternal medicineSickle cell anemiaDiseaseClinical trialAnemiaGastroenterologyPulmonary hypertensionKidneyPathologyAlternative medicineChronic thromboembolic pulmonary hypertensionHemoglobinopathies and Related DisordersErythropoietin and Anemia TreatmentPulmonary Hypertension Research and Treatments
Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1–2 trial | Litcius